Abstract 5257: Durable clinical and radiographic responses in a series of patients with HER2+ Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd)
Laura Alder(Duke Medical Center), Sarah Sammons(Dana-Farber Cancer Institute), Mustafa Khasraw(Northwestern University), Nancy U. Lin(Dana-Farber Cancer Institute), Amanda Van Swearingen, Dario Trapani(Harvard University), Carey K. Anders(Duke University)
Cited by 5
Related Papers
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
|Cancer Discovery|2019|1.4k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k